imm-124e
Animal productexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2014 (NCT02316717)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetImmunity, passive
immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- imm-124e
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05933525 | Phase 2 | May 29, 2023 | Department of Defense, Immuron Ltd., United States Navy |
| NCT03042767 | Phase 2 | Feb 1, 2017 | Advanced MR Analytics AB, Emory University, Immuron Ltd. |
| NCT02316717 | Phase 2 | Dec 1, 2014 | Immuron Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Immuron Ltd. | For profit | 3 | 2 | 1 | 2014 |
| Advanced MR Analytics AB | For profit | 1 | 0 | 1 | 2017 |
| Department of Defense | Government | 1 | 0 | 1 | 2023 |
| Emory University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| United States Navy | Government | 1 | 0 | 1 | 2023 |
5 organizations
Page 1 / 1